Tesofensine
Also known as: NS2330
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A small-molecule triple monoamine reuptake inhibitor (not a peptide) originally developed for neurological disease and later studied for obesity.
What it is & how it works
What it is
Tesofensine is a small-molecule triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) — not a peptide. It was first developed for neurological disease, then studied for obesity after weight loss was noticed.
How it works
By raising levels of three neurotransmitters, it acts centrally to suppress appetite — a mechanism closer to older centrally-acting weight drugs than to GLP-1 agents.
The evidence and the caveat
There is phase-2 human weight data, but it is not a broadly approved therapy, and its monoamine mechanism carries cardiovascular and mood considerations that differ from incretins. Non-trial product is unapproved and unverified.
What it's discussed & studied for
- Obesity / weight management (investigational)
- Appetite suppression
Discussion of a use is not a claim that it works or is approved.
Research status
Investigational for obesity, with phase-2 human weight-loss data. Originally trialed for Parkinson's/Alzheimer's. Not broadly approved for weight.
Evidence quality
Human phase-2 data exists for weight, but the compound is not a broadly approved therapy and longer-term/large-scale data is limited.
Dosing discussion
Defined within clinical trials; no broadly approved weight-loss label.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
As a monoamine reuptake inhibitor it can affect heart rate, blood pressure, and mood — a different risk profile than incretins. Not a broadly approved weight therapy.
Sourcing literacy
Not a peptide and not a broadly approved drug; research-market product is unapproved and unverified.
Selected literature
FAQ
Is tesofensine a GLP-1 drug?
No. It's a small-molecule triple monoamine reuptake inhibitor with a completely different mechanism than incretin therapies. It's grouped here as a metabolic/weight compound.
Is it approved for weight loss?
It is investigational for obesity and not a broadly approved weight-loss therapy.